BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 17659826)

  • 1. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.
    Mandel S; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2007 Aug; 82(6):348-60. PubMed ID: 17659826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
    Reznichenko L; Amit T; Zheng H; Avramovich-Tirosh Y; Youdim MB; Weinreb O; Mandel S
    J Neurochem; 2006 Apr; 97(2):527-36. PubMed ID: 16539659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
    Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
    Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
    FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis.
    Dedeoglu A; Cormier K; Payton S; Tseitlin KA; Kremsky JN; Lai L; Li X; Moir RD; Tanzi RE; Bush AI; Kowall NW; Rogers JT; Huang X
    Exp Gerontol; 2004; 39(11-12):1641-9. PubMed ID: 15582280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Review on the neuroprotective effects of green tea polyphenols for the treatment of neurodegenerative diseases].
    Li Q; Li Y
    Wei Sheng Yan Jiu; 2010 Jan; 39(1):123-6. PubMed ID: 20364607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
    Mandel SA; Avramovich-Tirosh Y; Reznichenko L; Zheng H; Weinreb O; Amit T; Youdim MB
    Neurosignals; 2005; 14(1-2):46-60. PubMed ID: 15956814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region.
    Venti A; Giordano T; Eder P; Bush AI; Lahiri DK; Greig NH; Rogers JT
    Ann N Y Acad Sci; 2004 Dec; 1035():34-48. PubMed ID: 15681799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Estrogen: regulation of amyloid-beta protein metabolism and attenuation of amyloid-beta protein neurotoxicity].
    Zhang S; Yao T
    Sheng Li Ke Xue Jin Zhan; 2003 Jul; 34(3):197-201. PubMed ID: 14628462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG.
    Avramovich-Tirosh Y; Reznichenko L; Mit T; Zheng H; Fridkin M; Weinreb O; Mandel S; Youdim MB
    Curr Alzheimer Res; 2007 Sep; 4(4):403-11. PubMed ID: 17908043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.
    Weinreb O; Mandel S; Amit T; Youdim MB
    J Nutr Biochem; 2004 Sep; 15(9):506-16. PubMed ID: 15350981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
    Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
    J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models.
    Amit T; Bar-Am O; Mechlovich D; Kupershmidt L; Youdim MBH; Weinreb O
    Neuropharmacology; 2017 Sep; 123():359-367. PubMed ID: 28571715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
    Maczurek A; Hager K; Kenklies M; Sharman M; Martins R; Engel J; Carlson DA; Münch G
    Adv Drug Deliv Rev; 2008; 60(13-14):1463-70. PubMed ID: 18655815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate.
    Weinreb O; Amit T; Youdim MB
    Free Radic Biol Med; 2007 Aug; 43(4):546-56. PubMed ID: 17640565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
    Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
    J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action.
    Gasparini L; Ongini E; Wenk G
    J Neurochem; 2004 Nov; 91(3):521-36. PubMed ID: 15485484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
    Zhang HY; Tang XC
    Trends Pharmacol Sci; 2006 Dec; 27(12):619-25. PubMed ID: 17056129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.